175 related articles for article (PubMed ID: 29496287)
1. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma.
Hamada S; Fuseya Y; Tsukino M
Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):346-348. PubMed ID: 29496287
[No Abstract] [Full Text] [Related]
2. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
Robinson SD; Lai C; Hotton G; Anand G
Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
[TBL] [Abstract][Full Text] [Related]
3. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
Vallet H; Gaillet A; Weiss N; Vanhaecke C; Saheb S; Touitou V; Franck N; Kramkimel N; Borden A; Touat M; Ricard D; Verny M; Maisonobe T; Psimaras D
Ann Oncol; 2016 Jul; 27(7):1352-3. PubMed ID: 26940685
[No Abstract] [Full Text] [Related]
5. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
6. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
7. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab induced toxic epidermal necrolysis.
Kumar R; Bhandari S
Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
[No Abstract] [Full Text] [Related]
9. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
[No Abstract] [Full Text] [Related]
10. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
11. Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
Hashimoto K; Kaira K; Kawasaki T; Yamaguchi O; Kagamu H
Lung Cancer; 2020 Jan; 139():221-223. PubMed ID: 31806361
[No Abstract] [Full Text] [Related]
12. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma.
Shikano K; Kaneko K; Kaburaki K; Isobe K; Kawabe K; Homma S; Kawai S; Nanki T
Scand J Rheumatol; 2020 Jan; 49(1):82-83. PubMed ID: 31135242
[No Abstract] [Full Text] [Related]
14. Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.
Nakano Y; Koide N; Koyama Y; Nitta K; Koizumi T
Thorac Cancer; 2021 Feb; 12(4):557-559. PubMed ID: 33350050
[TBL] [Abstract][Full Text] [Related]
15. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
Akagi Y; Awano N; Inomata M; Kuse N; Tone M; Yoshimura H; Jo T; Takada K; Kumasaka T; Izumo T
Intern Med; 2020 Apr; 59(8):1075-1080. PubMed ID: 32009093
[TBL] [Abstract][Full Text] [Related]
16. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
17. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
[No Abstract] [Full Text] [Related]
18. [A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery].
Tsujita T; Takahashi S; Oinuma T; Hata N
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1641-1644. PubMed ID: 30449854
[TBL] [Abstract][Full Text] [Related]
19. Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.
Imai R; Ono M; Nishimura N; Suzuki K; Komiyama N; Tamura T
J Thorac Oncol; 2019 Feb; 14(2):e36-e38. PubMed ID: 30391574
[No Abstract] [Full Text] [Related]
20. Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumab.
Khan AM; Munir A; Thalody V; Munshi MK; Mehdi S
Immunotherapy; 2019 Dec; 11(18):1533-1540. PubMed ID: 31815569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
